A history of other malignancy =< 2 years previous; exceptions are malignancies with a negligible risk of metastasis or death (e.g., expected 5-year overall survival [OS] > 90%) that were treated with an expected curative outcome, such as squamous cell carcinoma of the skin, in-situ carcinoma of the cervix uteri, non-melanomatous skin cancer, carcinoma in situ of the breast, incidental histological finding of prostate cancer (tumor, node, metastasis [TNM] stage of T1a or T1b) or synchronous head and neck (H&N) primaries
History of prior invasive malignancy diagnosed within 3 years prior to study enrollment; exceptions are malignancies with a negligible risk of metastasis or death (e.g., expected 5-year OS > 90%) that were treated with an expected curative outcome, such as squamous cell carcinoma of the skin, in-situ carcinoma of the cervix uteri, non-melanomatous skin cancer, carcinoma in situ of the breast, or incidental histological finding of prostate cancer (TNM stage of T1a or T1b)
Prior history of malignancies, other than MDS or AML, unless the subject has been free of the disease for >= 1 year; however, subjects with the following history/concurrent conditions are allowed: basal or squamous cell carcinoma of the skin; carcinoma in situ of the cervix; carcinoma in situ of the breast; incidental histologic finding of prostate cancer (T1a or T1b using the tumor, node, metastasis [TNM] clinical staging system)
Curatively treated incidental prostate cancer (T1/T2a)
Subject has prior history of malignancies, other than MM, unless the subject has been free of the disease for >= 5 years with the exception of the following malignancies:\r\n* Basal cell carcinoma of the skin\r\n* Squamous cell carcinoma of the skin\r\n* Carcinoma in situ of the cervix\r\n* Carcinoma in situ of the breast\r\n* Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, node, metastasis [TNM] clinical staging system) or prostate cancer that is curative
Subject has any other malignancy within 5 years prior to randomization. Exceptions include the following: squamous cell carcinoma of the skin, in-situ carcinoma of the cervix, uteri, non-melanomatous skin cancer, carcinoma in situ of the breast, or incidental histological finding of prostate cancer (TNM stage of T1a or T1b) â€” all treatments that should have been completed 6 months prior to signing ICF.
Subject has no other malignancy within 5 years, except non-melanoma skin cancer, cervical intraepithelial neoplasia, or in-situ cervical cancer or incidental histological finding of prostate cancer (TNM stage of T1a or T1b); all treatments of which should have been completed 6 months prior to signing ICF.
Incidental histologic finding of prostate cancer (T1a or T1b using the TNM [tumor, nodes, metastasis] clinical staging system) or prostate cancer that is curative
Prior history of cancer, other than MDS, unless the subject has been free of the disease for ? 3 years. (Basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the breast, and incidental histologic finding of prostate cancer) (T1a or T1b using the tumor, nodes, metastasis [TNM] clinical staging system is allowed)
Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis [Tumor, node, metastases (TNM)] clinical staging system).
Incidental histological finding of prostate cancer (TNM stage of T1a or T1b)
Incidental histologic finding of prostate cancer (TNM stage of T1a or T1b)
Incidental histologic finding of prostate cancer (TNM stage of T1a or T1b)
Incidental histologic finding of prostate cancer (TNM stage of T1a or T1b)
Incidental histologic finding of prostate cancer (TNM stage of T1a or T1b).
Subject has any other malignancy within 5 years prior to signing the ICF. Exceptions include the following: squamous cell carcinoma of the skin, in-situ carcinoma of the cervix, uteri, non-melanomatous skin cancer, carcinoma in situ of the breast, or incidental histological finding of prostate cancer (Tumor, node and metastasis (TNM) stage of T1a or T1b). All treatment should have been completed 6 months prior to signing ICF.
Incidental histological finding of prostate cancer (TNM stage of T1a or T1b)
Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis [TNM] clinical staging system)
Incidental histologic finding of prostate cancer (T1a or T1b using the TNM [tumor, nodes, metastasis] clinical staging system) or prostate cancer that is curative.
Subject has prior history of malignancies, other than MM, unless the subject has been free of the disease or >= 5 years with the exception of the following malignancies\r\n* Basal cell carcinoma of the skin\r\n* Squamous cell carcinoma of the skin\r\n* Carcinoma in situ of the cervix\r\n* Carcinoma in situ of the breast\r\n* Incidental histologic finding of prostate cancer (T1a or T1b using the TNM clinical staging system) or prostate cancer that is curative
